Free teleconferences: Newly Diagnosed and Advancing Therapies for Blood Cancers

NHL: A Guide to Treatment for the Newly Diagnosed

Location:
Free Teleconference/Webcast
Date: June 15, 2010 - Tuesday

Beginning Time: 12:00 pm Eastern
End Time: 1:30 pm
Event Description:

Register for this free telephone/webcast education program. This program will feature John P. Leonard, MD, The Richard T. Silver Distinguished Professor of Hematology and Medical Oncology, Weill Cornell Medical College, New York, NY.

Participants will have the opportunity to ask the presenter questions during the program.

This program is sponsored by The Leukemia & Lymphoma Society and supported by grants from Genentech & Biogen Idec in collaboration with Abrale.

For more information contact:
Information Resource Center
(800) 955-4572
infocenter@lls.org

Partners in Progress: An Expert Panel Discussion on Advancing Therapies for Blood Cancers

Free In-Person Education Program
Date: June 22, 2010 - Tuesday

Beginning Time: 5:30 pm Eastern
End Time: 7:30 pm

Register to participate by telephone or webcast.

Register to participate in person at Hackensack University Medical Center, Hekemian Conference Center, Hackensack, NJ.

This program will feature Gail J. Roboz, MD, Director, Leukemia Program, Associate Professor of Medicine and Maria Baldo, MS, PA-C, Senior Physician Assistant, Leukemia Service both from Weill Cornell Medical College of Cornell University in New York and Stuart L. Goldberg, MD, Chief, Division of Leukemia, John Theurer Cancer Center, Hackensack University Medical Center, Associate Clinical Professor of Medicine, University of Medicine & Dentistry of New Jersey and Louis J. DeGennaro, PhD, Executive Vice President and Chief Mission Officer, The Leukemia & Lymphoma Society, White Plains, New York and John J. Hughes, MDS Survivor and Clinical Trial Participant from Bayonne, New Jersey.

Participants will have the opportunity to ask the presenters a question during the program.

This program is sponsored by The Leukemia & Lymphoma Society and supported by an educational grant from Genentech and Biogen Idec and also supported by an educational donation from Amgen.

Blog Category: 

More Articles

More Articles

Amazon.com is pleased to have the Lymphoma Information Network in the family of Amazon.com associates. We've agreed to ship items...

The question ought to be what are myelodysplastic syndromes (MDS), since this is a group of similar blood and bone marrow diseases that...

Merkel Cell Carcinoma (MCC) is a very rare and aggressive skin cancer that usually develops when a person is in his or her 70s. It is...

Radiation Therapy Topics

...

At some point, the Seattle biotech company Cell Therapeutics Inc (CTI) should earn an entry in the Guinness Book of World Records for utter and...

Site Beginnings

This site was started as Lymphoma Resource Page(s) in 1994. The site was designed to collect lymphoma...

Three papers appearing in the journal Blood and pointing towards a regulator-suppressor pill could offer hope to blood cancer...

The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...

The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...

The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...

According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...

Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...

New research suggests that frontline radioimmunotherapy...

Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...

Sitemap